Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

International prognostic index-based outcomes for diffuse large B-cell lymphomas.

Richard B Wilder1, Maria A Rodriguez, L Jeffrey Medeiros

  • 1Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. rwilder@mdanderson.org

Cancer
|July 13, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study.

Blood neoplasia·2026
Same author

Serum proteomic and single-cell transcriptomic profiling reveals immunoproteomic features distinguishing early-stage mycosis fungoides from atopic dermatitis.

The Journal of investigative dermatology·2026
Same author

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Leukemia & lymphoma·2026
Same author

Staging imaging reveals clinically significant comorbidities in primary cutaneous marginal zone lymphoma: A retrospective study.

Journal of the American Academy of Dermatology·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Cutaneous B-Cell lymphoma incidence trends in the United States: A surveillance, epidemiology, and end results analysis of 10,975 cases.

The Journal of investigative dermatology·2026

Doxorubicin chemotherapy with or without radiotherapy improved outcomes for diffuse large B-cell lymphoma (DLBCL) patients. The International Prognostic Index (IPI) significantly predicted survival, with lower IPI scores correlating to better progression-free and overall survival rates.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Trials

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
  • Doxorubicin-based chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), is a standard treatment.
  • The International Prognostic Index (IPI) is used to predict outcomes in DLBCL patients.

Purpose of the Study:

  • To evaluate the efficacy of doxorubicin-based chemotherapy with or without involved-field radiotherapy in DLBCL patients.
  • To assess the impact of the International Prognostic Index (IPI) on treatment outcomes.
  • To inform ongoing clinical trials for DLBCL management.

Main Methods:

  • Prospective treatment of 294 patients with large B-cell or T-cell lymphomas from 1988-1996.

Related Experiment Videos

  • Reclassification of diagnoses according to the World Health Organization (WHO) classification.
  • Treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, with or without involved-field radiotherapy (39.6 Gy median dose).

    • Main Results:

    • A total of 224 patients had DLBCL, including 24 with primary mediastinal large B-cell lymphoma.
    • The International Prognostic Index (IPI) significantly stratified patients by progression-free, cause-specific, and overall survival (P < 0.003).
    • Five-year survival rates for IPI 0-2 (n=212) were 73% (progression-free), 84% (cause-specific), and 82% (overall), compared to 37%, 33%, and 32% for IPI 3-4 (n=12).

    Conclusions:

    • Doxorubicin-based chemotherapy and radiotherapy demonstrate significant impact on DLBCL patient survival.
    • The IPI is a critical factor in predicting DLBCL patient outcomes.
    • Current clinical trials are investigating intensified chemotherapy and immunotherapy (rituximab) for specific DLBCL patient subgroups.